Skip to main content

Table 4 Breast cancer-specific mortality associated with the ER/PR/HER2 score

From: Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women

ER/PR/HER2 scorea Number of women Number of deaths Adjusted HR (95% CI)
Model 1b Model 2c
Women with ER-negative invasive breast cancer  
Overall     
  < 0 60 15 Referent Referent
 0 337 103 1.32 (0.76 to 2.32) 1.30 (0.74 to 2.28)
  > 0 109 39 1.43 (0.77 to 2.69) 1.43 (0.76 to 2.67)
 Trend    Ptrend = 0.30 Ptrend = 0.29
White women     
  < 0 35 9 Referent Referent
 0 162 46 1.20 (0.55 to 2.62) 1.09 (0.48 to 2.45)
  > 0 54 14 1.16 (0.46 to 2.90) 1.09 (0.43 to 2.76)
 Trend    Ptrend = 0.79 Ptrend = 0.88
Black women     
  < 0 25 6 Referent Referent
 0 175 57 1.46 (0.59 to 3.61) 1.47 (0.60 to 3.64)
  > 0 55 25 1.57 (0.61 to 4.06) 1.55 (0.60 to 4.03)
 Trend    Ptrend = 0.42 Ptrend = 0.45
Homogeneity of trends between white women and black women Phomogeneity = 0.36 Phomogeneity = 0.32
Women with ER-positive invasive breast cancer
Quartiles of ER/PR/HER2 scored     
Overall     
 Q1 175 18 Referent Referent
 Q2 177 22 1.27 (0.65 to 2.45) 1.39 (0.71 to 2.70)
 Q3 172 33 2.04 (1.10 to 3.81) 2.00 (1.07 to 3.76)
 Q4 174 42 2.71 (1.48 to 4.95) 2.48 (1.36 to 4.55)
 Trend    Ptrend = 0.0002 Ptrend = 0.001
White women     
 Q1 118 9 Referent Referent
 Q2 105 10 1.41 (0.53 to 3.74) 1.37 (0.52 to 3.62)
 Q3 113 20 2.03 (0.84 to 4.92) 1.98 (0.82 to 4.78)
 Q4 94 23 2.77 (1.19 to 6.45) 2.62 (1.12 to 6.11)
 Trend    Ptrend = 0.01 Ptrend = 0.01
Black women     
 Q1 57 9 Referent Referent
 Q2 72 12 1.32 (0.50 to 3.51) 1.60 (0.58 to 4.45)
 Q3 59 13 2.34 (0.85 to 6.42) 2.34 (0.83 to 6.55)
 Q4 80 19 3.43 (1.33 to 8.84) 2.88 (1.08 to 7.67)
 Trend    Ptrend = 0.006 Ptrend = 0.03
Homogeneity of trends between white women and black women Phomogeneity = 0.56 Phomogeneity = 0.32
  1. CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.
  2. aER/PR/HER2 score = 94.7 × (–0.100 ER10 – 0.079 PR10 + 0.586 HER2); the range of ER/PR/HER2 scores was –71.07 to 55.49 in women with ER-negative tumor and –141.10 to 53.92 in women with ER-positive tumor.
  3. bMultivariable Cox proportional hazards regression models using age (in days) as the time metric stratified by age (in years) and adjusted for race (white, black), study site (Detroit, Los Angeles), tumor stage (localized, non-localized).
  4. cAdditionally adjusted for histologic grade (low, intermediate, high); low and intermediate were combined into a single category in analyses for women with ER-negative tumors due to a small number of women with a low grade.
  5. dQuartiles of ER/PR/HER2 scores in all women with ER-positive tumors were Q1 (–141.10 to –97.33), Q2 (–97.32 to –68.98), Q3 (–68.97 to –36.66), and Q4 (–36.65 to 53.92).